Intellia Therapeutics Inc [NTLA] stock prices are up 3.08% to $26.08 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NTLA shares have gain 3.90% over the last week, with a monthly amount drifted -12.98%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 18, March 2024, Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy. In a post published today on Yahoo Finance, Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient dosed in the global pivotal, Phase 3 MAGNITUDE trial of NTLA-2001. NTLA-2001 is an investigational in vivo CRISPR-based therapy designed as a single-dose treatment to inactivate the TTR gene and thereby prevent the production of TTR protein for the treatment of transthyretin (ATTR) amyloidosis. The MAGNITUDE trial is evaluating the efficacy and safety of NTLA-2001 in patients with ATTR amyloidosis with cardiomyopathy.
From an analyst’s perspective:
Intellia Therapeutics Inc [NASDAQ: NTLA] stock has seen the most recent analyst activity on February 23, 2024, when Goldman downgraded its rating to a Neutral and also revised its price target to $32 from $136. On April 13, 2023, Canaccord Genuity initiated with a Buy rating and assigned a price target of $66 on the stock. Bernstein started tracking the stock assigning a Outperform rating and suggested a price target of $54 on March 21, 2023. BMO Capital Markets upgraded its rating to a Outperform and raised its price target to $57 on March 14, 2023. Cantor Fitzgerald started tracking with a Overweight rating for this stock on February 01, 2023, and assigned it a price target of $67. In a note dated January 24, 2023, Citigroup upgraded an Neutral rating on this stock and revised its target price from $48 to $39.
The stock price of Intellia Therapeutics Inc [NTLA] has been fluctuating between $22.67 and $47.48 over the past year. Currently, Wall Street analysts expect the stock to reach $131.76 within the next 12 months. Intellia Therapeutics Inc [NASDAQ: NTLA] shares were valued at $26.08 at the most recent close of the market. An investor can expect a potential return of 405.21% based on the average NTLA price forecast.
Analyzing the NTLA fundamentals
The Intellia Therapeutics Inc [NASDAQ:NTLA] reported sales of 36.27M for trailing twelve months, representing a drop of -114.12%. Gross Profit Margin for this corporation currently stands at 0.75% with Operating Profit Margin at -14.21%, Pretax Profit Margin comes in at -13.27%, and Net Profit Margin reading is -12.97%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.43 and Total Capital is -0.43. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.53 points at the first support level, and at 24.97 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.44, and for the 2nd resistance point, it is at 26.79.
Intellia Therapeutics Inc [NTLA] reported earnings per share of -$1.46 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.45/share, meaning a difference of -$0.01 and a surprise factor of -0.70%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$1.38 per share as compared to estimates of -$1.5 per share, a difference of $0.12 representing a surprise of 8.00%.
Ratios To Look Out For
It’s worth pointing out that Intellia Therapeutics Inc [NASDAQ:NTLA]’s Current Ratio is 8.67. In addition, the Quick Ratio stands at 8.67 and the Cash Ratio stands at 1.97. Considering the valuation of this stock, the price to sales ratio is 69.11, the price to book ratio is 2.31.
Transactions by insiders
Recent insider trading involved BASTA JAMES, EVP, General Counsel, that happened on Mar 04 ’24 when 2297.0 shares were sold. EVP, Chief Technical Officer, Clark Eliana completed a deal on Mar 04 ’24 to sell 605.0 shares. Meanwhile, EVP, Chief Scientific Officer Sepp-Lorenzino Laura sold 2275.0 shares on Jan 08 ’24.
